Virtual Library

Start Your Search

M. Attia



Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      49P - Computed tomographic features of pulmonary sarcomatoid carcinoma (ID 499)

      12:30 - 13:00  |  Author(s): M. Attia

      • Abstract

      Background:
      Pulmonary sarcomatoid carcinoma is a rare tumor. It is subdivided into 5 subtypes and representing approximately 0.4% of non-small cell lung cancer. The aim of our work is to illustrate the computed tomography (CT) features of this tumor.

      Methods:
      This was a retrospective case series of 18 consecutive patients with a pulmonary sarcomatoid carcinoma, collected between January 2011 and December 2016. All patients had undergone a CT scan for the diagnosis, staging and therapeutic response evaluation. CT- guided percutaneous biopsy and a histological analysis were performed in all cases for the pathological confirmation.

      Results:
      The mean age of patients was 56.8 years (range, 46-73 years). The CT appearance of the tumor was similar for all our patients: Large mass, peripheral, heterogeneous density, with massive necrotic tissue component that strongly heightened after contrast injection; tumor had a locoregional extension with parietal and bone invasion (n = 5) and a distance extension (n = 4) to the adrenal glands. Pathological examination found a pleomorphic carcinoma (n = 3), a giant cell carcinoma (n = 1) and a carcinosarcoma (n = 2). Sarcomatoid carcinoma diagnosis was increased for the remaining patients without precision of histological subtype.

      Conclusions:
      Pulmonary sarcomatoid carcinoma seems to have CT scan characteristics that distinguish it from other non-small cell lung cancers, specifically: diagnosis size, peripheral necrosis and increased vascularization of its fleshy portion with a local aggressiveness and a high metastatic potential.

      Clinical trial identification:


      Legal entity responsible for the study:
      Abderrahmen Mami Hospital

      Funding:
      Abderrahmen Mami Hospital

      Disclosure:
      All authors have declared no conflicts of interest.